Jazz Pharmaceuticals names Renee Gala as next CEO

DUBLIN - Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a $6.75 billion biopharmaceutical company with impressive gross profit margins of 92%, announced Thursday that Renee Gala will become the company’s new President and Chief Executive Officer effective August 11, 2025, succeeding co-founder Bruce Cozadd who is retiring from the position.

Gala, who currently serves as President and Chief Operating Officer, will also join the company’s Board of Directors. Cozadd, who informed the Board of his retirement plans in December 2024, will remain as Chairperson of the Board. According to InvestingPro analysis, Jazz Pharmaceuticals maintains strong financial health with an overall score of "GREAT," suggesting solid operational foundation for the leadership transition.

The appointment follows what the company described as a thorough succession planning process that evaluated both internal and external candidates. Gala joined Jazz in 2020 as Chief Financial Officer before being promoted to her current role in October 2023.

"I am honored to step into the CEO role and build upon Jazz’s extraordinary legacy," said Gala in the company’s press release. She currently oversees Jazz’s global business operations, including commercial, medical, research and development, and technical operations.

Prior to joining Jazz, Gala served as CFO at GRAIL Inc. and Theravance Biopharma. She also held various roles at Eli Lilly and Company between 2001 and 2006. Gala currently serves on the Board of Directors of DexCom.

Cozadd, who co-founded Jazz 22 years ago, expressed confidence in his successor, noting Gala’s leadership has been "critical in Jazz’s transformation into a high-growth biopharmaceutical company."

Jazz Pharmaceuticals specializes in treatments for sleep disorders, epilepsy, and cancer. The company is headquartered in Dublin, Ireland, with operations in multiple countries. Currently trading below its Fair Value according to InvestingPro analysis, the company generates annual revenue of $4.06 billion and trades at an attractive P/E ratio of 14.5. For deeper insights into Jazz Pharmaceuticals’ valuation and growth prospects, including 8 additional ProTips, check out the comprehensive Pro Research Report available on InvestingPro.

The information in this article is based on a press release statement from Jazz Pharmaceuticals.

In other recent news, Jazz Pharmaceuticals has made significant strides with its cancer treatments. The European Commission has granted conditional marketing authorization for Jazz Pharmaceuticals’ Ziihera (zanidatamab) for treating HER2-positive biliary tract cancer, marking it as the first HER2-targeted therapy approved for this indication in the EU. This decision was based on the Phase 2b HERIZON-BTC-01 trial, which demonstrated a notable objective response rate and median overall survival among patients. Concurrently, Jazz Pharmaceuticals announced the U.S. FDA’s acceptance of a Priority Review for their supplemental New Drug Application for Zepzelca in combination with atezolizumab as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC). The Phase 3 IMforte study showed that this combination significantly improved survival rates, reducing the risk of disease progression or death by 46%. Analyst firms such as Stifel and UBS have maintained a Buy rating on Jazz Pharmaceuticals’ stock, reflecting confidence in the company’s ongoing developments and potential future performance. This optimism is bolstered by positive trial results and anticipated data read-outs that could further strengthen Jazz Pharmaceuticals’ position in the oncology market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.